Published in Eur J Cancer on February 27, 2007
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.79
Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer (2009) 1.51
Post-mortem tissue biopsies obtained at minimally invasive autopsy: an RNA-quality analysis. PLoS One (2014) 1.51
Procurement of Human Tissues for Research Banking in the Surgical Pathology Laboratory: Prioritization Practices at Washington University Medical Center. Biopreserv Biobank (2011) 1.29
Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics (2010) 1.27
The Infectious Diseases BioBank at King's College London: archiving samples from patients infected with HIV to facilitate translational research. Retrovirology (2009) 1.05
Effects of delay in the snap freezing of colorectal cancer tissues on the quality of DNA and RNA. J Korean Soc Coloproctol (2010) 1.03
Basic principles and technologies for deciphering the genetic map of cancer. World J Surg (2009) 0.96
The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. Clin Biochem (2014) 0.90
Tumor biobanks in translational medicine. J Transl Med (2012) 0.89
Detection of predation using qPCR: effect of prey quantity, elapsed time, chaser diet, and sample preservation on detectable quantity of prey DNA. J Insect Sci (2009) 0.88
Biobanking research on oncological residual material: a framework between the rights of the individual and the interest of society. BMC Med Ethics (2013) 0.85
Significance of biological resource collection and tumor tissue bank creation. World J Gastrointest Oncol (2010) 0.84
Biobanking in a constantly developing medical world. ScientificWorldJournal (2013) 0.84
Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors. Endocr Connect (2013) 0.80
A study of the role of the FOXP2 and CNTNAP2 genes in persistent developmental stuttering. Neurobiol Dis (2014) 0.78
Renal tissue thawed for 30 minutes is still suitable for gene expression analysis. PLoS One (2014) 0.77
Superficial scrapings from breast tumors is a source for biobanking and research purposes. Lab Invest (2014) 0.76
Tissue banking in a regional hospital: a promising future concept? First report on fresh frozen tissue banking in a hospital without an integrated institute of pathology. World J Surg (2012) 0.75
Multicenter fresh frozen tissue sampling in colorectal cancer: does the quality meet the standards for state of the art biomarker research? Cell Tissue Bank (2017) 0.75
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (2001) 5.75
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer (2001) 3.10
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg (2001) 2.94
Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med (1996) 2.35
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet (2002) 2.00
Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res (1998) 1.96
Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol (2000) 1.96
Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res (1996) 1.95
Bcl-2 protein expression in follicular lymphomas in absence of 14;18 translocation. Lancet (1990) 1.86
CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene (1996) 1.85
bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer (1994) 1.81
Ineffectiveness of AL721 in HIV disease. Lancet (1990) 1.73
bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood (1992) 1.69
Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3-kinase. J Biol Chem (1995) 1.58
Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol (1994) 1.58
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer (2009) 1.57
Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol (1997) 1.55
Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer (2003) 1.55
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet (2003) 1.52
LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood (1994) 1.48
The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol (2012) 1.46
The challenge of providing spectacles in the developing world. Community Eye Health (2000) 1.45
The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene (1995) 1.43
Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis (2000) 1.42
The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol (1986) 1.41
Chemotherapy for colorectal cancer. J R Soc Med (2000) 1.40
5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment? Br J Cancer (1989) 1.39
Cytotoxic-loaded albumin microspheres: a novel approach to regional chemotherapy. Br J Surg (1988) 1.36
Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer (1996) 1.33
Pseudohyperkalaemia. Br Med J (Clin Res Ed) (1985) 1.32
MicroRNA expression in lymphocyte development and malignancy. Leukemia (2008) 1.30
Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1 alpha in vivo. Blood (1992) 1.27
The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res (1996) 1.25
Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer (2005) 1.24
Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer (2009) 1.22
Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res (1998) 1.21
TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network. Eur J Cancer (2006) 1.20
Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res (1986) 1.19
Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res (1997) 1.18
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res (1993) 1.18
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol (2005) 1.17
Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. J Clin Oncol (1998) 1.16
p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer (1994) 1.16
Expression of HIV in lymph node cells of LAS patients. Immunohistology, in situ hybridization, and identification of target cells. Am J Pathol (1988) 1.16
Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer (2002) 1.16
Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol (1996) 1.15
Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol (1996) 1.14
Structural requirements for bone resorption by endotoxin and lipoteichoic acid. J Dent Res (1975) 1.14
Molecular typing of bacteria directly from cerebrospinal fluid. Eur J Clin Microbiol Infect Dis (2000) 1.13
Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer (1996) 1.13
Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry (2001) 1.12
Home delivery: chemotherapy and pizza? BMJ (2001) 1.09
Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res (2001) 1.09
The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology (2003) 1.09
Lymphoid and epithelial markers in small cell anaplastic thyroid tumours. J Clin Pathol (1985) 1.09
Regional chemotherapy for colorectal liver metastases: a phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver metastases. Br J Surg (1990) 1.07
The use of angiotensin II as a potential method of targeting cytotoxic microspheres in patients with intrahepatic tumour. Br J Cancer (1991) 1.07
Immunohistochemical demonstration of p24 HTLV III major core protein in different cell types within lymph nodes from patients with lymphadenopathy syndrome (LAS). Histopathology (1986) 1.06
In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther (2001) 1.06
Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases. Br J Cancer (1988) 1.05
Angiogenesis in myelodysplastic syndromes. Br J Cancer (1999) 1.05
Flow dynamics in a lethal anterior communicating artery aneurysm. AJNR Am J Neuroradiol (2000) 1.05
The TERT variant rs2736100 is associated with colorectal cancer risk. Br J Cancer (2012) 1.05
Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology (2005) 1.05
Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res (1999) 1.04
Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br J Cancer (1991) 1.04
Inhibition of influenza virus formation by a peptide that corresponds to sequences in the cytoplasmic domain of the hemagglutinin. Virology (1991) 1.04
Hepatocellular carcinoma. Ann Oncol (2001) 1.03
Neural network and regression predictions of 5-year survival after colon carcinoma treatment. Cancer (2001) 1.03
Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J Control Release (1999) 1.02
Arteriovenous shunting of microspheres in patients with colorectal liver metastases: errors in assessment due to free pertechnetate, and the effect of angiotensin II. Nucl Med Commun (1987) 1.02
The epidemiology of thyroid carcinoma. Crit Rev Oncog (1993) 1.02
TuBaFrost 3: regulatory and ethical issues on the exchange of residual tissue for research across Europe. Eur J Cancer (2006) 1.01
Amylase and protease secretion by the marine bacterium Vibrio gazogenes. Aust J Biol Sci (1982) 1.00
Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma. Histopathology (2002) 0.99
Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother Pharmacol (1987) 0.99
Angiotensin II as a potential method of targeting cytotoxic-loaded microspheres in patients with colorectal liver metastases. Br J Cancer (1991) 0.99
Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. Cytometry (1992) 0.99
Establishing a national tissue bank for surgically harvested cancer tissue. Br J Surg (2004) 0.99
A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation. Histopathology (2007) 0.98
Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun (1995) 0.98
Hepatic arterial chemotherapy for metastatic colorectal carcinoma. Br J Cancer (1994) 0.98
A two-phase case-control study for colorectal cancer genetic susceptibility: candidate genes from chromosomal regions 9q22 and 3q22. Br J Cancer (2011) 0.97
Simultaneous phenotypically distinct but clonally identical mucosa-associated lymphoid tissue and follicular lymphoma in a patient with Sjögren's syndrome. Blood (1999) 0.97
Anti-proliferative activity and mechanism of action of titanocene dichloride. Br J Cancer (1998) 0.97
Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther (1998) 0.97
Flow dynamics in a fatal aneurysm of the basilar artery. AJNR Am J Neuroradiol (1996) 0.96
Comparative intracellular uptake of adriamycin and 4'-deoxydoxorubicin by non-small cell lung tumor cells in culture and its relationship to cell survival. Biochem Pharmacol (1986) 0.94
Multiple-strain colonization in nasal carriers of Staphylococcus aureus. J Clin Microbiol (2014) 0.94